摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氯-4-三氟甲氧基苯甲醛 | 83279-39-4

中文名称
3-氯-4-三氟甲氧基苯甲醛
中文别名
3-氯-4-(三氟甲基)苯甲醛;4-氨基-2,3-二氟苯腈;3-氯-4-三氟甲基苯甲醛
英文名称
3-chloro-4-(trifluoromethoxy)benzaldehyde
英文别名
3-chloro-4-trifluoromethoxybenzaldehyde;3-chloro-4-(trifluoromethoxy)-benzaldehyde
3-氯-4-三氟甲氧基苯甲醛化学式
CAS
83279-39-4
化学式
C8H4ClF3O2
mdl
MFCD01631561
分子量
224.567
InChiKey
SDBUQQVMQXOGBO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    226℃
  • 密度:
    1.463
  • 闪点:
    92.3℃

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2913000090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335

SDS

SDS:b72a9a255d30a1ffec993b4697627eff
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Chloro-4-(trifluoromethoxy)benzaldehyde
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-Chloro-4-(trifluoromethoxy)benzaldehyde
CAS number: 83279-39-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H4ClF3O2
Molecular weight: 224.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF<br/>[FR] BENZAMIDES SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
    申请人:GENENTECH INC
    公开号:WO2015078374A1
    公开(公告)日:2015-06-04
    The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    这项发明提供了具有一般式I的化合物及其药用盐,其中变量RA、RAA、下标n、环A、X2、L、下标m、X1、R1、R2、R3、R4、R5和RN的含义如本文所述,并包含这种化合物的组合物和使用这种化合物和组合物的方法。
  • PYRAZOLOPYRIMIDINE COMPOUND
    申请人:MITSUBISHI TANABE PHARMA CORPORATION
    公开号:US20150239889A1
    公开(公告)日:2015-08-27
    Provided is a pyrazolopyrimidine compound represented by formula (I) having an HIF-PHD inhibitory effect, or a pharmaceutically acceptable salt thereof. [In the formula, represents an optionally substituted 7-hydroxypyrazolo[4,3-d]pyrimidine-5-yl, X represents a simple bond or an optionally substituted straight-chain alkylene, Z represents hydrogen atom, or formula (i), formula (ii) or formula (iii) and rings A and A′ are independently an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted alicyclic hydrocarbon, or an optionally substituted non-aromatic heterocycle.]
    提供的是一种具有HIF-PHD抑制效果的吡唑并嘧啶化合物,其由公式(I)表示,或其药用可接受的盐。[在公式中,代表一个可选地取代的7-羟基吡唑并[4,3-d]嘧啶-5-基,X代表一个简单键或一个可选地取代的直链亚烷基,Z代表氢原子,或公式(i),公式(ii)或公式(iii)和环A和A'分别独立地代表一个可选地取代的芳香族,一个可选地取代的杂芳族,一个可选地取代的脂肪环烃,或一个可选地取代的非芳香族杂环]。
  • [EN] ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] ISOXAZOLINES EN TANT QU'INHIBITEURS DE L'HYDROLASE DES AMIDES D'ACIDES GRAS
    申请人:INFINITY PHARMACEUTICALS INC
    公开号:WO2010135360A1
    公开(公告)日:2010-11-25
    The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
    本发明提供了式(I)的异噁唑啉FAAH抑制剂或其药用可接受形式,其中G、Ra、Rb、Rc和Rd中的每一个如本文所定义。本发明还提供了包括式(I)化合物或其药用可接受形式以及药用可接受赋形剂的药物组合物。本发明还提供了治疗FAAH介导疾病的方法,包括向需要的受试者施用式(I)化合物或其药用可接受形式的治疗有效量。
  • [EN] CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES<br/>[FR] ARYLALKYLAMINES MODULANT UN RECEPTEUR CALCIQUE
    申请人:AMGEN INC
    公开号:WO2003099776A1
    公开(公告)日:2003-12-04
    The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    该发明的化合物由以下一般结构(I)或其药用可接受盐所代表,以及含有它们的组合物,其中变量在此处定义,并且它们的用途是减少或抑制PTH分泌,包括减少或抑制PTH分泌的方法以及用于治疗或预防与骨骼疾病相关的疾病的方法,例如骨质疏松症,或与PTH过度分泌相关的疾病,例如甲状旁腺功能亢进症。该主题发明还涉及制备此类化合物的过程,以及在此类过程中有用的中间体。
  • 3-(Fluorovinyl)pyrazoles and their use
    申请人:HÄRTER Michael
    公开号:US20130150325A1
    公开(公告)日:2013-06-13
    The present application relates to novel 3-(fluorovinyl)pyrazole derivatives, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.
    本申请涉及新颖的3-(氟乙烯基)吡唑衍生物,涉及它们的制备方法,涉及它们用于治疗和/或预防疾病的使用,以及用于制备用于治疗和/或预防疾病的药物,特别是用于治疗和/或预防增殖性和血管生成性疾病以及那些由于对缺氧状态的代谢适应而产生的疾病。此类治疗可以作为单一疗法进行,也可以与其他药物或进一步的治疗措施相结合进行。
查看更多